Champions Oncology (NASDAQ:CSBR) posted its earnings results on Thursday, March 15th. The biotechnology company reported ($0.01) earnings per share for the quarter, Bloomberg Earnings reports. The company had revenue of $5.08 million during the quarter. Champions Oncology had a negative return on equity of 854.38% and a negative net margin of 17.17%.
Champions Oncology stock traded down $0.22 on Friday, reaching $3.60. The company’s stock had a trading volume of 49,711 shares, compared to its average volume of 35,805. Champions Oncology has a twelve month low of $2.19 and a twelve month high of $4.75.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/champions-oncology-csbr-issues-quarterly-earnings-results.html.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.